• If you are wondering whether Amgen's current share price lines up with its underlying value, this article walks through the numbers so you can judge for yourself.
• Amgen recently closed at US$377.00, with returns of a 1.5% decline over 7 days, 10.3% over 30 days, 15.1% year to date, 24.5% over 1 year, 81.1% over 3 years and 92.6% over 5 years, which may catch the eye of investors thinking about growth potential and shifting risk perceptions.
• Recent headlines around Amgen have focused on its position as a large biotech name within the pharmaceuticals and biotech sector, and how it fits into broad investor interest in established healthcare companies. This context, along with sector-level discussion, helps frame why the stock's longer-term returns may be drawing fresh attention now.
• On our valuation checklist, Amgen scores 4 out of 6. Next we will walk through what that means across different valuation approaches, before finishing with a way to look at valuation that can give you an even clearer view of the stock.

Approach 1: Amgen Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and discounting them back to today’s value using a required rate of return.

For Amgen, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $8.44b. Analysts have provided free cash flow estimates out to 2030, for example $12.43b in 2026 and $15.77b in 2030. Simply Wall St then extrapolates further years beyond the explicit analyst coverage.

After discounting these projected cash flows, the model arrives at an estimated intrinsic value of about $646.49 per share. Against the recent share price of $377.00, this implies the stock is around 41.7% undervalued based on this DCF framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Amgen is undervalued by 41.7%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: Amgen Price vs Earnings

For profitable companies like Amgen, the P/E ratio is a useful shorthand because it links what you pay per share to the earnings the business is already producing. Investors usually accept a higher P/E when they expect stronger growth or see less risk, and a lower P/E when growth expectations are lower or risks feel higher.

Amgen currently trades on a P/E of 26.36x. That is above the broader Biotechs industry average of 21.75x, but below the peer group average of 42.07x. Simply Wall St also calculates a proprietary “Fair Ratio” of 28.96x for Amgen, which is the P/E level suggested by factors such as its earnings profile, profit margins, industry, market cap and risk characteristics.

This Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for company specific traits rather than treating all biotech names as interchangeable. Comparing Amgen’s current P/E of 26.36x with the Fair Ratio of 28.96x indicates that the shares are trading below that tailored reference level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Amgen Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple tool on Simply Wall St’s Community page where you connect your story about Amgen to a set of forecast numbers and a Fair Value that you can compare directly with today’s price.

With a Narrative, you spell out what you think will shape Amgen, link that to specific expectations for future revenue, earnings and margins, and the platform turns those assumptions into a Fair Value that updates automatically when fresh news, earnings or guidance arrive.

For example, one current Amgen Narrative assumes a Fair Value of US$432.00 per share based on confidence in areas such as obesity and cardiovascular drugs. Another takes a much more cautious stance with a Fair Value of about US$230.89. Seeing those different Fair Values side by side against the latest share price helps you decide whether you currently see Amgen closer to the optimistic story or the more risk focused one.

For Amgen however we will make it really easy for you with previews of two leading Amgen Narratives:

Fair Value in this bullish narrative: US$432.00 per share

Implied discount or premium to the recent US$377.00 share price: about 12.7% below this narrative fair value

Revenue growth assumption: 4.70% a year

• Frames Amgen as a company where obesity, cardiovascular and other late stage programs could support higher revenue and profit margins than consensus assumes.
• Highlights AI supported R&D, an expanded product set and a broad global footprint as reasons earnings and cash generation could be stronger over time.
• Flags risks around pricing pressure, patent expiries, R&D productivity and acquisition execution, but still sees room for a higher fair value than the current share price.

Fair Value in this bearish narrative: about US$230.89 per share

Implied discount or premium to the recent US$377.00 share price: about 63.3% above this narrative fair value

Revenue growth assumption: 5.37% annual decline

• Focuses on reliance on aging therapies, upcoming patent expiries and expanding biosimilar competition as potential headwinds for future revenue and margins.
• Points to pricing pressure, higher spending needs and acquisition risks as reasons earnings and free cash flow could be tighter than some investors expect.
• Acknowledges that the pipeline, efficiency gains and long term healthcare trends could offset some of these pressures, but still arrives at a lower fair value than the current share price.

These two Narratives show how the same set of facts can support very different conclusions about Amgen's value. Your own view will sit somewhere on that spectrum, based on how you weigh the pipeline, pricing risks, spending plans and long term demand for the therapies Amgen develops.

Do you think there's more to the story for Amgen? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.